Vanda Pharmaceuticals | VNDA - PE Price to Earnings


Vanda Pharmaceuticals reported 16.79 in PE Price to Earnings for its fiscal quarter ending in June of 2023.





Pe Change Date
Acadia Pharmaceuticals 10.08 1.53 Mar/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Akebia Therapeutics 1.63K 1.6K Dec/2025
Alnylam Pharmaceuticals 80.04 90.66 Mar/2026
Anika Therapeutics 47.54 27.2 Jun/2024
AstraZeneca 29.59 2.3 Mar/2026
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Eli Lilly 40.27 0.06 Mar/2026
Esperion Therapeutics 129.79 129 Dec/2024
Halozyme Therapeutics 11.35 11.8 Mar/2026
J&J 24.53 0.91 Mar/2026
Lexicon Pharmaceuticals 12.44 4.73 Jun/2021
Ligand Pharmaceuticals 56.5 26.8 Mar/2026
Merck 16.52 2.6 Mar/2026
Moderna 27.22 14.51 Jun/2023
Novartis 17.79 1.74 Dec/2025
Pfizer 9.32 5.16 Mar/2026
PTC Therapeutics 9.98 3.25 Dec/2025
Puma Biotechnology 13.93 44.88 Jun/2024
Sanofi 11.84 0.14 Mar/2026
Takeda 46.52 188.53 Mar/2026
Teva Pharmaceutical Industries 10.07 0.04 Mar/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023
Veracyte 24.89 20.41 Mar/2026